Posts

European Commission Approves Merck's ENFLONSIA (clesrovimab) for RSV Prevention in Infants

on

JPM26 Day 3: Sanofi CEO on RSV Scrutiny and Regeneron Dupixent Defense

on

FDA reviews safety of approved RSV antibodies for infants

on

Co-Diagnostics Initiates Clinical Evaluations for Upper Respiratory Multiplex Point-of-Care Test on Co-Dx PCR Platform to Support Submission to the U.S. FDA

on

Enanta Presses Ahead with RSV Drug Zelicapavir Despite Missing Primary Endpoint in Phase IIb Trial

on

Sanofi Tightens Grip on RSV with $1.15B Upfront Acquisition of Vicebio, Diversifying Beyond mRNA Vaccines

on

RFK Jr.'s Revamped ACIP Votes Against Thimerosal in Flu Vaccines, Signaling Shift in Vaccine Policy

on

ACIP Backs Merck's Enflonsia for RSV Prevention in Infants

on

Merck Wins FDA Approval for RSV Antibody Drug, Intensifying Market Competition

on

Merck’s Enflonsia FDA Approval Spurs Sanofi to Accelerate Beyfortus Supply Ahead of 2025-26 RSV Season

on

CDC advisors broaden RSV vaccine recommendations to at-risk adults in their 50s

on

Sanofi's Beyfortus Achieves Blockbuster Status, Poised for Further Growth in US Market

on